# Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer

> **NCT04489940** · PHASE2 · TERMINATED · sponsor: **EMD Serono Research & Development Institute, Inc.** · enrollment: 11 (actual)

## Conditions studied

- Triple Negative Breast Neoplasms

## Interventions

- **DRUG:** Bintrafusp alfa

## Key facts

- **NCT ID:** NCT04489940
- **Lead sponsor:** EMD Serono Research & Development Institute, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2020-10-12
- **Primary completion:** 2022-01-27
- **Final completion:** 2022-07-08
- **Target enrollment:** 11 (ACTUAL)
- **Why stopped:** The study was prematurely discontinued by the sponsor due to probability of success which was too low to justify the continuation of recruitment.
- **Last updated:** 2023-04-10

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04489940

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04489940, "Bintrafusp Alfa in High Mobility Group AT-Hook 2 (HMGA2) Expressing Triple Negative Breast Cancer". Retrieved via AI Analytics 2026-06-22 from https://api.ai-analytics.org/clinical/NCT04489940. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*